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Matt Lamkin and Carl Elliott
About a week after Maran Wolston was pre-scribed Copaxone, a drug for multiple sclero-sis (MS), she got a phone call from a nurse at
an organization called Shared Solutions. The organi-
zation was familiar to Wolston; when her neurologist
had asked permission to share her health information
with Shared Solutions, Wolston had agreed, assuming
it was connected to her health insurance.
The nurse who called Wolston was checking in to
see how the treatment was going. It was not going
well. While Copaxone is not typically associated with
some of the unpleasant side effects of other MS drugs,
it does have at least one serious drawback: the drug
must be injected every day. The injections can be bru-
tally painful. "No matter where I injected the drug
each day, the injection site swelled up into a huge welt
and felt like a gigantic bee sting," Wolston writes. "I
don't ordinarily use a cane to walk, but every time I
injected Copaxone somewhere in my legs, I needed a
cane just to move around my house."
The Shared Solutions nurse gave Wolston some
suggestions about adjusting her injection technique.
She also asked if Wolston would be interested in talk-
ing to a fellow patient who could share her experiences
with Copaxone and answer Wolston's questions about
living with MS. Wolston agreed. A few days later, she
got a call from an elderly woman who had been taking
Copaxone for several years. The woman heaped praise
on Copaxone and emphasized the importance of tak-
ing the drug religiously. Soon the woman was calling
so frequently that Wolston began to get curious.
It did not take her long to discover that Shared Solu-
tions is an arm of Teva Neuroscience, the pharmaceu-
tical company that sells Copaxone. The Shared Solu-
tions nurse was a Teva employee whose job was to keep
Wolston taking Copaxone, as was the elderly patient
"peer" who called. Even Wolston's neurologist, who
prescribed her Copaxone, was in Teva's employ. He
had taken more than $70,000 from the drug-maker
in the previous two years, in the form of speaker fees,
honoraria, and "promotional/marketing and consult-
ing" fees for Teva. This may explain why none of these
people ever suggested that she discontinue treatment
or change to another drug. Wolston writes, "Maybe I'm
old-fashioned, but as a patient I felt that the party who
should have been helping was my neurology clinic, not
a division of a pharmaceutical company"
For a long time, drug companies have marketed
their drugs primarily by persuading doctors to write
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more prescriptions - either by sending armies of drug
reps into clinics and hospitals, or by saturating the air-
waves with ads imploring people to request drugs by
their brand names. The strategy has worked well. But
there is a drag on profits: many people do not take the
drugs they have been prescribed. Increasingly drug
companies are trying to remedy that shortcoming
through programs that increase patient "adherence"
with their prescriptions. These efforts, like Shared
Solutions, offer emotional support and technical
expertise from people patients trust, including health
care professionals like nurses and pharmacists. From
Non-adherence reprsets a serious fina
blw tohe phar aeutical industry too
much a s $564 billion in revenue
if you believe Capgemni Consulting. No
doubt this is why pha ma ceutical compa
have begun to hir dediated patient
adherence teams" and drug market erc
sponsorin nnual "patient adherencer ,
advocacy onferences.
the patients' perspective these interactions can look
like medical care. But these programs are being run
out of drug companies' marketing departments. The
"support" these programs offer is all geared toward
one goal: getting patients to get their prescriptions
filled and refilled, preferably in perpetuity.
Justifying Adherence
Efforts to get independent-minded patients to fol-
low their doctors' instructions are nothing new. Until
recently the problem was known as "non-compliance;'
a phrase that took hold in the late 1950s. During the
1980s and 1990s, however, the notion of "non-com-
pliance" took a beating from social scientists and bio-
ethicists, who complained that it reinforced a pater-
nalistic, authoritarian model of the doctor-patient
relationship.2 By the early 2000s, the word "compli-
ance" had started to sound anachronistic enough to
warrant replacement by a new word: "adherence.'
The word "adherence" has been embraced by the
pharmaceutical industry, which is often careful to
distinguish adherence from compliance in its promo-
tional materials. In a document on adherence to spe-
cialty products, for instance, IMS Health claims that
adherence and compliance have "precise and some-
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what different meanings." Compliance is simply fol-
lowing a treatment regimen as prescribed - taking the
correct dose at the right time of day. Adherence, how-
ever, is continuing to follow the treatment instructions
over the correct period of time - whether it is two
weeks, a year, or indefinitely.3 Whether this represents
a genuinely significant difference or mere rebrand-
ing matters little to the underlying imperative behind
adherence, which IMS Health defines as the "extent to
which a patient follows medical instructions.'
Whatever term is used, it should be acknowledged
that failure to follow medical instructions can dam-
age patients' health, especially when
the patients have a chronic illness for
which there is a proven therapy. Today
,neial nearly half of all Americans suffer from a
as chronic illness of some sort, such as dia-
betes and heart disease, and nearly three
quarters of U.S. health care expenditures
are spent caring for these individuals.4
Lnies Many of these illnesses can be managed
effectively if patients stick closely to drug
regimens prescribed by their doctors. Yet
many patients fail to do that. In a 2003
nd report on patient adherence to prescrip-
tion medications, the World Health
Organization estimated that only about
half of patients suffering from chronic
illnesses take their medications as pre-
scribed.6 This can result in acute complications. By one
estimate, mortality rates for "non-adherent" patients
with heart disease or diabetes are nearly double the
rates for "adherent" patients.6
Non-adherence can also be costly. In fact, it has
become customary for any writer who argues for the
importance of adherence strategies to emphasize the
enormous costs of non-adherence, generally in the
first paragraph of the article. "Approximately 30%
to 50% of US adults are not adherent to long-term
medications leading to an estimated $100 billion in
preventable [hospital admissions] costs annually,"
according to a recent article in JAMA.7 The New Eng-
land Healthcare Institute (NEHI) puts the figure even
higher. It estimates patient non-adherence is respon-
sible for as much as $290 billion in avoidable medical
spending each year, or approximately 13% of total U.S.
health care expenditures.!
Of course, it is probably no coincidence that NEHI's
members include Merck, AstraZeneca, GlaxoSmith-
Kline, and many other drug companies. Non-adher-
ence represents a serious financial blow to the phar-
maceutical industry too - as much as $564 billion a
year in revenue losses, if you believe Capgemini Con-





nies have begun to hire "dedicated patient adherence
teams" and drug marketers are sponsoring annual
"patient adherence and advocacy" conferences. From
2009 to 2012, American pharmaceutical companies
increased their budget allocations for patient adher-
ence by 281%.1o
In pharma's telling, these efforts are simply a way of
doing well by doing good. Since increasing adherence
with prescription medications is supposed to improve
patient health, increasing drug sales can be packaged
as a form of public service. Armed with the logic that
more drug consumption yields healthier people, phar-
maceutical marketers glide easily from "better patient
outcomes" to "better brand performance.' In a press
release, McKesson Corporation explained that its
success in boosting sales proved that "pharmaceuti-
caps, which fit on standard pharmaceutical bottles,
are equipped with microchips and transmitters that
send information to the internet via wireless routers.14
Patients, caregivers, or pharmacists can program the
caps, entering the proper times for the medications to
be taken. When that time arrives, a light on the cap
blinks. If the patient fails to open the bottle within a
few minutes, the cap prompts the patient by playing a
ring tone. If the patient still has not opened the bottle
within an hour, Vitality follows up with an automated
phone call. Vitality also knows when a prescription is
(or should be) empty, and automatically orders a refill
from the pharmacy.
Investing in a comprehensive adherence program
pays off best for expensive specialty drugs. As the pres-
ident of one company that runs adherence programs
People do not trust drug companies. When Harris Interactive conducted
a poll asing respondents, "Which of these industries do you think are
genrally honest and trustworthy - so that you normally believe a statement
by a company in that industry" only 12% placed the pharmaceutical industry
in that category., As result, drug makers ar now trying to deliver their
marketing messae s through trusted itermediaries - including
nurses, pharmacists, and even fellow patients.
cal manufacturers can effectively drive brand perfor-
mance and patient loyalty through improvement of
patient health outcomes.",
The logic of this approach - where drug adher-
ence, brand loyalty, and patient health all merge into
a seamless whole - can be seen clearly in "Your Way,"
Pfizer's adherence program for Toviaz, a treatment
for overactive bladder. Pfizer conducted clinical tri-
als to establish the efficacy not only of the drug, but
of the Your Way adherence program. The company
suggested that if it could show that the program got
patients to take Toviaz more consistently, then the
company could report that fact on the drug's label.12
The more effective the marketing, the reasoning goes,
the more effective the drug.
Not all adherence problems require elaborate
adherence programs. In cases where non-adherence
comes from patients forgetting to take their medi-
cation, for example, the solution can be relatively
straightforward. A well-known example is the Dial-
pak, a circular blister pack first introduced in 1963
to help women remember to take a birth control pill
every day.13 GlowCaps, pill bottle tops sold by Vital-
ity, Inc., take this concept several steps further. These
put it, "Candidly, the higher the price of the drug the
more likely that somebody is going to do this. You're
not going to be doing this for Tums."15 Many of these
programs encourage adherence to drugs that patients
really hate to take. For example, MS patients who take
Rebif (interferon beta la) can suffer flu-like symptoms
such as nausea, vomiting, and stomach pain after each
of their three weekly injections. They can escape those
side effects by choosing Copaxone, but only if they are
willing to inject themselves daily and endure occa-
sional welts, hives, and other unpleasant reactions.
To get people to take an enormously expensive drug
that produces painful side effects and may offer few
beneficial effects - and to do so every day, for the rest of
their lives - requires changing people's "beliefs, inten-
tions, and values."16 Drug companies have learned that
DTC advertising cannot do that. Adherence programs
for these drugs require repeated, personal interactions
with people whom patients trust. People do not trust
drug companies. When Harris Interactive conducted
a poll asking respondents, "Which of these industries
do you think are generally honest and trustworthy -
so that you normally believe a statement by a company
in that industry," only 12% placed the pharmaceutical
JOURNAL OF LAW, MEDICINE & ETHICS494
Lamkin and Elliott
industry in that category.17 As a result, drug makers
are now trying to deliver their marketing messages
through trusted intermediaries - including nurses,
pharmacists, and even fellow patients.
Nurses and Patients as Drug Reps
In the old days, to the extent drug companies paid
attention to adherence at all, they did so using demo-
graphic data. For example, they relied on research
indicating older patients are more likely to struggle
with managing several different medications, while
younger patients are more likely to be deterred by out-
of-pocket costs. But there are limits to this approach,
since reasons for non-adherence vary on an individual
basis and, at least according to one marketer, are "cor-
related with patients' perceptions, beliefs, and attitudes
toward taking their medications rather than their age
or income."" So for drugs that are profitable enough
to justify the expense, drug companies are turning to
nurses, pharmacists, and "patient ambassadors" to tai-
lor and deliver "frequent, personalized interactions"
with patients in order to promote adherence.19
Most makers of expensive specialty drugs have
established drug-specific call centers staffed by nurses,
including the makers of MS drugs, such as Shared
Solutions for Copaxone, MS Lifelines for Rebif, and
ActiveSource for Tysabri. Patients who have been pre-
scribed one of these drugs can call and ask questions
about how to use the drug or manage its side effects.
Unlike the medical professionals who are being paid
by patients' insurers, however, who limit their time
consulting with patients because of low reimburse-
ment rates, these nurses are willing to spend time
with patients and offer emotional support. And unlike
ordinary nurses or doctors, pharma's nurses can be
reached 24 hours a day, 7 days a week. They also make
outgoing calls to check up on patients and help them
work through any challenges they might be having in
sticking with the drug.
The reason this strategy works is simple: nurses
are the most trusted professionals in America.20 That,
together with their medical training and experience
dealing with patients, makes them ideal candidates
to counsel patients about sticking with their drugs.
"Nurses can quickly build a rapport with patients and
establish trust, allowing them to elicit information
and assess potential non-adherence risks;' a drug mar-
keting executive explains. "Patients are therefore more
likely to accept the information provided at face value
and are better able to integrate the information when
they make decisions regarding taking their medication
and follow-up appointments with their prescriber.'21
Since these call centers offer trained health care
professionals delivering medical advice, patients
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could be pardoned for believing they are receiving
medical care - a service whose fundamental purpose
is to promote their health. In fact, the companies run-
ning these programs actively encourage that belief.
McKesson Specialty Pharmaceutical's Kerr Hol-
brook described his company's nurse support line as
an extension of the physician's office."22 But the real
purpose is to ensure that customers stay loyal to the
brand - as evidenced by the fact that Mr. Holbrook
was a vice president in McKesson's marketing divi-
sion. According to an online posting seeking nurses
to staff the Rebif call center, for example, the nurse's
"main objective is to achieve customer satisfaction and
ensure customer retention." United BioSource Cor-
poration (UBC), a pharmaceutical support company,
touts its ability to leverage patients' trust in its nurses
to "provide personal, patient-centric care that inspires
brand loyalty"23
When nurses become part of the pharmaceutical
marketing machinery, they abdicate their ability to
speak frankly with patients regarding their own medi-
cal judgments. Unlike nurses whose job is to protect
patient health, who are free to discuss off-label uses
and offer their own opinions, drug company nurses
are restricted in what they can say by FDA rules gov-
erning drug promotion. Moreover, by virtue of their
employment, their duty to patients is rendered sec-
ondary to the goal of customer retention. For example,
faced with a patient who has bad reactions to Rebif, a
nurse whose main objective is to retain customers may
be more likely to suggest ways to lessen or cope with
the side effects - even when a nurse concerned only
with patient care might advise the patient to talk with
her doctor about changing her medication.
Like nurses, pharmacists have become "a key cog
in not only the pharmaceutical chain, but also in the
marketing of prescription drugs and services."24 Phar-
macists are effective at improving adherence because
patients trust them, ranking pharmacists second only
to nurses in terms of professional ethics and honesty.25
In addition, patients interact more with pharmacists
than any other health care professional.26 So pharma-
cists have many opportunities to influence patients
and identify the reasons individual patients are not
taking their medications. As pharmaceutical distrib-
utor McKesson says, pharmacists can offer "person-
alized messaging, program enrollment, behavioral
coaching and other clinical services at the point of
dispensing."27
McKesson provides these opportunities through its
Pharmacy Intervention Program, which uses behav-
ioral psychologists to train pharmacists in "motiva-
tional interviewing" - "a proven technique used to
uncover and help patients overcome adherence bar-
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riers."28 According to McKesson, pharmacists can be
trained to listen for "key words and phrases that signal
that patients are accepting the adherence messages"
and then to help patients build a plan of action, pre-
sumably one that will keep them on their medication.29
Noting that "non-adherence is not only detrimental to
patient health, but also to the health of your brand,"
McKesson boasts a strong return on investment for
drug companies who use this service - as measured
by increased drug consumption.30
Even patients are playing an increasingly impor-
tant role in pharmaceutical marketing. For example,
the pharmaceutical marketing firm Snow & Associ-
ates offers a program called Patient Ambassadors,
which identifies and trains patients to serve as spokes-
people for pharmaceutical brands. CEO Brenda
Snow explains that enlisting patients in marketing
efforts can address "the trust gap that currently exists
between pharmaceutical companies and their patient
consumers," lending "instant authenticity and cred-
ibility" to an industry that sorely needs them.31 As
Snow points out, even the best doctors may not give
patients the sense that they really understand what
having a chronic disease is like. "Connecting people
with others who have trodden a similar path is enor-
mously important."32
Not every patient makes a suitable ambassador for
a brand. As Snow says, they must be patients whose
"authentic stories align with the company's market-
ing strategies."33 This begins with careful selection of
patients, who are screened "according to brand speci-
fications."34 Once patients are selected, Snow works
closely with the Patient Ambassadors to tailor their
messages to align with the "brand strategy" of a phar-
maceutical industry client. In this way, the company
does not need to manipulate what patients say; it
merely needs to pick the right patients, who are telling
the right stories.
A key function of Patient Ambassadors is to keep
patients on a particular therapy for as long as possible.
As with nurse and pharmacist marketing programs,
ambassadors do this by seeking to change how patients
define success and think about harmful side effects.
A key role of patient peers, Snow urges, is to provide
other patients with strategies to "manage" those side
effects, so that patients "are more likely to approach
the side effects as hurdles instead of discontinuing
use in frustration."36 At the same time, communica-
tion from carefully selected patients "fosters belief in
a successful treatment outcome.' The basic idea is to
put forward real patients who are happy with the drug
to communicate the message that however unpleasant
the therapy may be, patients need to endure it to reach
the successful treatment outcome.
The Problem with Adherence
On the surface, improving patient adherence is all
gain and no pain. When people are more consistent
in taking drugs that are safe and highly effective in
treating serious conditions, patients improve their
health and drug companies increase their profits, all
while saving the health care system money. This sce-
nario has proven attractive not only to drug compa-
nies but to policymakers. Congress has authorized
employer-sponsored wellness programs to penalize
non-adherent employees with thousands of dollars
in increased premiums and deductibles.36 Last year,
JAMA published an article proposing that failure to
follow doctors' recommendations should itself be
considered a medical condition. The authors argued
that doctors should "treat" this medical condition by
"target[ing] interventions to the participant's adher-
ence barriers."'7
But as the JAMA authors noted, those "barriers"
include things like "the patient has concluded the
benefits of taking medications do not outweigh the
costs" and "the patient does not perceive medication
to have therapeutic efficacy." Indeed, the most com-
mon reason patients do not take their medication is
simply because they do not want to - usually because
they do not believe they need the medication or do not
like the side effects.38 Recasting objections to taking
medications as "barriers to adherence" that need to
be overcome with monetary penalties and behavioral
interventions ignores the fact that sometimes patients
have good reasons to decline their doctors' advice.
1. Ineffective and Dangerous
First, many common medical practices are based on
extremely limited evidence, and when they are sub-
jected to rigorous research, they are often reversed.39
Practices such as aggressive treatment of diabetes or
using statins for primary prevention have been shown
to pose serious risks without producing benefits.40 A
2010 study from the Archives of Internal Medicine
found that 58% of the drugs prescribed to elderly
patients could be discontinued and that these patients'
quality of life would improve as a result.41 An analy-
sis published in JAMA by John loannidis showed that
one-third of the efficacy claims made in highly-cited
journal articles published between 1990 and 2003
were either contradicted by subsequent clinical stud-
ies or found to have weaker effects than claimed in the
initial articles.42 And these numbers reflect only the
fraction of trials that researchers tried to replicate.
Many trials are never even challenged.43
Second, the very companies urging patients to
"adhere" to their medications may be hiding serious
risks. A prime example is GlaxoSmithKline (GSK)'s
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diabetes drug, Avandia. Although GSK had discovered
that Avandia was linked to increased risk of cardiovas-
cular disease as early as 1999, the company hid that
finding for 11 years while promoting the drug heav-
ily. In one internal email, a GSK executive wrote that
"[p]er Sr. Mgmt request, these data should not see the
light of day to anyone outside of GSK."44 It was not
until 2007 that the New England Journal ofMedicine
published an independent meta-analysis indicating
Avandia increased patients' risk of death from cardio-
vascular causes by 64%.46 According to a subsequent
independent study, between 1999 and 2009 Avandia
was responsible for 47,000 needless heart attacks,
strokes, heart failures, or deaths.46 In 2010 European
regulators pulled the drug off the market, and the FDA
placed severe restrictions on its availability.
2. Adherence Strategies andAntipsychotics
A similar issue has played out for the entire class of
drugs known as atypical antipsychotics. Non-adher-
ence with antipsychotics has been a problem since the
1950s, when these drugs were introduced for schizo-
phrenia. Although it was clear that antipsychotics
could reduce acute psychotic symptoms such as hal-
lucinations, delusions, and disordered thinking, they
could also cause serious long-term side effects. The
most troubling of these side effects are "extrapyra-
midal" symptoms such as muscle dystonia, akathi-
sia, and tardive dyskinesia, which can be permanent.
Many patients also simply find antipsychotics very
unpleasant to take on a daily basis. They say the drugs
make them feel sluggish, emotionally dead and zom-
bie-like.47 Many patients with schizophrenia will take
antipsychotics only until their immediate psychotic
symptoms disappear, at which point the unpleasant-
ness of taking the drugs starts to outweigh the appar-
ent benefits.
Over the years, health care workers have attempted
a broad array of tactics to persuade patients to stay on
their antipsychotics. Some are simple, such as text mes-
sage reminders or calendars. Others, such as compli-
ance therapy or cognitive-behavioral therapy, depend
on "behavioral modification.' British researchers have
had some success with a more direct approach: they
simply gave mentally ill patients money in exchange
for taking their medication.48 Perhaps the most novel
adherence strategy has come from a team funded
by Eli Lilly, the manufacturer of the antipsychotic
Zyprexa, which has developed a "computer-animated
humanoid agent" that simulates face-to-face conver-
sation with patients suffering from schizophrenia.49
A typical encounter begins with the humanoid agent
walking onto the patient's computer screen, greeting
the patient, and conducting a "social and empathic
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chat;' with questions such as, "Have you taken your
evening Prolixin yet today?"
While it is true that patients with schizophrenia do
not always make good decisions about their medica-
tions, especially when they are acutely psychotic, it is
also important to acknowledge that there is legitimate
controversy as to what the appropriate long-term
treatment for schizophrenia is.50 In the 2000s, anti-
psychotics became the most profitable class of drugs in
America, largely because of the claim that the newer,
atypical (or "second-generation") antipsychotics such
as Zyprexa, Seroquel, and Risperdal carried a minimal
risk of causing extrapyramidal side effects. That claim
has proven to be largely untrue. In fact, the indepen-
dent, federally funded CATIE study found not only
that the atypical antipsychotics were no more effective
than an older generic drug, but that the risk of extra-
pyramidal side effects was generallyjust as high.5 1
Enforcing adherence with the atypical antipsychot-
ics has also exposed patients to a whole range of hid-
den metabolic risks - namely diabetes, hyperglyce-
mia, and weight gain. The major manufacturers of
the atypical antipsychotics have all been forced to pay
record-breaking penalties for fraud, in part for hiding
these risks. Lilly paid a record-setting $1.4 billion in
federal penalties for fraudulent marketing of Zyprexa
in 2009; four years later, Johnson and Johnson paid
$2.2 billion to settle accusations that it had illegally
marketed Risperdal. In 2010, AstraZeneca was forced
to pay more than half a billion dollars in 2010 to settle
federal investigations into illegal marketing of Sero-
quel. The company allegedly paid kickbacks to doc-
tors as part of an effort to market the drug off-label for
conditions ranging from dementia to ADHD to post-
traumatic stress disorder.52
3. Individualized Risk-Benefit Calculus
Third, deciding whether to take a medication often
depends on a highly individual risk-benefit calculus.
Most medications involve trade-offs between disease
symptoms and drug side effects, between longevity
and quality of life, between comfort in the present and
potential long-term health gains. A decision not to
take a particular medication may simply be a rational,
informed decision based on personal experience and
values.
Consider Copaxone. As previously discussed,
patients taking the drug have to inject themselves with
hypodermic needles every day, and patient Maran
Wolston noted that these injections can cause pain-
ful welts. Some patients experience "immediate post-
injection reactions," which they describe as similar
to the feeling of a heart attack or severe panic attack.
These side effects may seem like reasonable sacri-
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fices in exchange for slowing the progression of MS.
But it is far from clear how many patients experience
that benefit. In the most favorable studies of Copax-
one's efficacy - the ones published by Teva - 34% of
patients taking Copaxone remained relapse-free dur-
ing the two-year study.5 So did 27% of the patients
on placebo. An evaluation by the Cochrane Collabo-
ration, a not-for-profit group that offers independent
analysis of drug efficacy, concluded that Copaxone was
not effective in treating the progressive form of MS,
and had "few beneficial effects" in patients with the
relapse-remitting form of the disease.64
their drugs treat. The tactic of third-party messaging
- inserting your marketing message in the mouth of
a credible third party - is a time-honored public rela-
tions technique dating back to the time of PR pioneer
Edward Bernays.55
If adherence programs are different, it is mainly
because they take this technique away from the realm
of pure communication and move it directly into the
business of patient care. Even if companies are tech-
nically "transparent" in disclosing their sponsorship
of these efforts, their effectiveness relies on blurring
the lines between drug promotion and medical care.
What is puzzling is how these adherence programs have largely escaped
critical scrutiny. Over the past 15 years, the reputation of pharmaceutical
companies has taken a public beating - partly because of litigation,
and partly because of sustained academic criticism. It has become clear
that pharmaceutical companies have buried unfavorable research data,
manipulated clinical trials, paid kickbacks to physicians, bullied
academic critics, and ghostwritten journal articles (and in at least one
case, an entire fake medical journal). The old claim that pharmaceutical
:ompanies' aim is to promote patients' health now seems laughably quaint,
Yet pharmaceutical adherence programs are flourishing.
From a systemic perspective, the difference between
27% and 34% may be strong evidence in favor of the
benefits of increasing Copaxone adherence among
patients, since fewer patients experiencing relapses
might save the health care system money. But from
the patient's perspective, the choice is far less clear.
Patients, not the health care system, must endure the
side effects and reduced quality of life that goes along
with these drugs. And while the system can benefit
from small changes in the number of patients expe-
riencing relapses, the odds of any individual patient
experiencing benefits from these drugs may be low.
Conclusion
Part of what distinguishes pharmaceutical adherence
programs from garden-variety direct-to-consumer
advertising is the way the marketing message is laun-
dered through trusted authorities. In a way, this is
nothing new to the pharmaceutical industry. For
decades, drug companies have hired academic physi-
cians to deliver marketing talks disguised as medical
education; they have employed medical ghostwriters
to produce promotional material disguised as journal
articles; and they have used celebrities to promote
"disease awareness" campaigns for the conditions
When patients get medical advice from medical pro-
fessionals, they naturally assume that the advice is
aimed first at promoting their health, rather than pro-
moting "brand loyalty:"
If there is a single reason these adherence programs
have worked so well, without any real backlash, it is the
premise that boosting adherence benefits patients. If
patients are supposed to be taking their medication,
then anything that helps them stay on the drugs can
be presented as inherently good. From a traditional
informed consent perspective, a choice not to take a
medication might be thought of as the patient exercis-
ing his autonomy. These days, that choice is called a
"barrier to adherence" - even if the choice is informed
and reasonable. And what might otherwise be seen
as unjustified manipulation or deception gets a pass
because it is in done in the name of improving health
and saving lives.
Of course, pharmaceutical adherence programs
are not geared toward promoting patient health, but
toward ensuring patients keep using a particular
drug. As market research consultants Frost & Sullivan
have acknowledged, "The most compelling reason to
invest in these tailored communications is to increase
return on investment (ROI) by keeping patients on
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the therapy longer."66 McKesson Patient Relationship
Solutions assures pharmaceutical companies that
the company's "adherence tactics" will "optimize the
performance of your brand.'67 And like other inten-
sive marketing strategies, pharmaceutical adherence
programs are generally implemented only for new,
expensive, on-patent drugs. This is important to keep
in mind when hearing arguments about how boost-
ing adherence will save money for the health care sys-
tem. Preventing a stroke can save a lot of money, but it
saves more money to prevent a stroke with an effective
generic than an on-patent drug.
What is puzzling is how these adherence programs
have largely escaped critical scrutiny. Over the past 15
years, the reputation of pharmaceutical companies has
taken a public beating - partly because of litigation,
and partly because of sustained academic criticism. It
has become clear that pharmaceutical companies have
buried unfavorable research data, manipulated clinical
trials, paid kickbacks to physicians, bullied academic
critics, and ghostwritten journal articles (and in at least
one case, an entire fake medical journal).6 The old
claim that pharmaceutical companies' aim is to pro-
mote patients' health now seems laughably quaint. Yet
pharmaceutical adherence programs are flourishing.
The success of these programs is symptomatic of the
larger ills plaguing our health care system. Thanks in
part to the pharmaceutical industry's relentless push
toward overtreatment and expensive, on-patent medi-
cations, drug companies are the only entities with the
resources to give patients this kind of intensive, per-
sonalized support. For patients, receiving this kind of
attention from drug companies may be preferable to
not receiving it at all. Likewise, time-pressed health
care professionals and cash-strapped patient support
groups may be grateful for the assistance. Indeed, the
National Multiple Sclerosis Society ended its own
patient support program "because the drug companies
were doing such a thorough job."69 And to policymak-
ers desperate to reduce health care costs, the promise
of adherence programs - to promote health without
cutting services - may be too attractive to resist.
But as with most devil's bargains, the price is likely
to be steep. Medical professionals have built a vast
reservoir of public trust by acting as fiduciaries with
duties to protect patient health. Building that kind of
trust is a long and arduous process. Squandering it is
quick and easy. All it will take is for patients to dis-
cover that the people they have entrusted with their
care are salesmen in lab coats. And when even fellow
patients are part of pharma's marketing team, patients
will be left with nowhere to turn for independent
medical advice.
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